• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics

tetano

Editor, Senior Moderator
Drug Discov Today. 2018 Jan 12. pii: S1359-6446(17)30343-4. doi: 10.1016/j.drudis.2018.01.028. [Epub ahead of print]
[h=1]Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics.[/h] Zhou Z[SUP]1[/SUP], Liu T[SUP]1[/SUP], Zhang J[SUP]1[/SUP], Zhan P[SUP]2[/SUP], Liu X[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] The influenza RNA-dependent RNA polymerase (RdRP) is conserved among different types of influenza virus, playing an important part in transcription and replication. In this regard, influenza RdRP is an attractive target for novel anti-influenza drug discovery. Herein, we will introduce the structural and functional information of influenza polymerase; and an overview of inhibitors targeting the PA endonuclease and PB2 cap-binding site is provided, along with the approaches utilized for identification of these inhibitors. The protein-protein interactions (PPIs) of the three polymerase subunits: PA, PB1 and PB2, are described based on the published crystal structures, and inhibitors targeting the PA-PB1 interaction are introduced briefly.


[h=4]KEYWORDS:[/h] PA endonuclease; PB2 cap-binding site; PPI; Polymerase; drug design

PMID: 29339107 DOI: 10.1016/j.drudis.2018.01.028
 
Back
Top Bottom